MX2013006319A - Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek. - Google Patents
Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek.Info
- Publication number
- MX2013006319A MX2013006319A MX2013006319A MX2013006319A MX2013006319A MX 2013006319 A MX2013006319 A MX 2013006319A MX 2013006319 A MX2013006319 A MX 2013006319A MX 2013006319 A MX2013006319 A MX 2013006319A MX 2013006319 A MX2013006319 A MX 2013006319A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- compositions
- treating cancer
- mek
- pi3k
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan procedimientos para tratar pacientes con cáncer, en donde los procedimientos comprenden administrar al paciente una cantidad eficaz de un inhibidor de MEK y una cantidad eficaz de un inhibidor de PI3K. También se describen composiciones en las que los inhibidores de MEK y de PI3K están en combinación.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42146510P | 2010-12-09 | 2010-12-09 | |
US201161436258P | 2011-01-26 | 2011-01-26 | |
US201161467485P | 2011-03-25 | 2011-03-25 | |
FR1159940 | 2011-11-03 | ||
PCT/US2011/063871 WO2012078832A1 (en) | 2010-12-09 | 2011-12-08 | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013006319A true MX2013006319A (es) | 2013-07-03 |
Family
ID=45464841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013006319A MX2013006319A (es) | 2010-12-09 | 2011-12-08 | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek. |
Country Status (22)
Country | Link |
---|---|
US (1) | US20140024653A1 (es) |
EP (1) | EP2648729A1 (es) |
JP (1) | JP2013544892A (es) |
KR (1) | KR20140011311A (es) |
CN (1) | CN103402518A (es) |
AR (1) | AR084216A1 (es) |
AU (1) | AU2011338354A1 (es) |
BR (1) | BR112013014198A2 (es) |
CA (1) | CA2820748A1 (es) |
CL (1) | CL2013001643A1 (es) |
CR (1) | CR20130246A (es) |
DO (1) | DOP2013000131A (es) |
MA (1) | MA34815B1 (es) |
MX (1) | MX2013006319A (es) |
NZ (1) | NZ611581A (es) |
PE (1) | PE20140702A1 (es) |
RU (1) | RU2013131241A (es) |
SG (1) | SG190368A1 (es) |
TW (1) | TW201306837A (es) |
UY (1) | UY33790A (es) |
WO (1) | WO2012078832A1 (es) |
ZA (1) | ZA201303687B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013243429A1 (en) * | 2012-04-06 | 2014-10-23 | Merck Patent Gmbh | Methods for treating cancer using PI3K inhibitor and MEK inhibitor |
CA2887628C (en) * | 2012-10-11 | 2020-09-08 | Merck Patent Gmbh | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor |
FI3698790T3 (fi) | 2014-02-07 | 2023-06-06 | Verastem Inc | Menetelmiä epänormaalin solukasvun hoitamiseksi |
WO2016014390A1 (en) * | 2014-07-25 | 2016-01-28 | Merck Patent Gmbh | Compositions and methods for mek inhibitor combination therapy in the treatment of cancer |
CN111433604B (zh) | 2017-12-22 | 2023-12-08 | 瑞士商艾迪安纳股份有限公司 | 用于确定抗cd26配体的生物活性的定量细胞方法 |
JP2022547358A (ja) | 2019-09-13 | 2022-11-14 | ジ インスティテュート オブ キャンサー リサーチ:ロイヤル キャンサー ホスピタル | 治療組成物、組み合わせ、及び使用方法 |
CN116568330A (zh) * | 2020-10-16 | 2023-08-08 | 纪念斯隆-凯特琳癌症中心 | 用于癌症治疗的铁死亡诱导 |
US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
-
2011
- 2011-12-07 AR ARP110104595A patent/AR084216A1/es unknown
- 2011-12-08 AU AU2011338354A patent/AU2011338354A1/en not_active Abandoned
- 2011-12-08 JP JP2013543331A patent/JP2013544892A/ja not_active Abandoned
- 2011-12-08 CA CA2820748A patent/CA2820748A1/en not_active Abandoned
- 2011-12-08 MX MX2013006319A patent/MX2013006319A/es not_active Application Discontinuation
- 2011-12-08 NZ NZ611581A patent/NZ611581A/en not_active IP Right Cessation
- 2011-12-08 SG SG2013039367A patent/SG190368A1/en unknown
- 2011-12-08 TW TW100145212A patent/TW201306837A/zh unknown
- 2011-12-08 EP EP11806025.0A patent/EP2648729A1/en not_active Withdrawn
- 2011-12-08 BR BR112013014198A patent/BR112013014198A2/pt not_active IP Right Cessation
- 2011-12-08 PE PE2013001394A patent/PE20140702A1/es not_active Application Discontinuation
- 2011-12-08 CN CN2011800671706A patent/CN103402518A/zh active Pending
- 2011-12-08 KR KR1020137017879A patent/KR20140011311A/ko not_active Application Discontinuation
- 2011-12-08 WO PCT/US2011/063871 patent/WO2012078832A1/en active Application Filing
- 2011-12-08 RU RU2013131241/15A patent/RU2013131241A/ru not_active Application Discontinuation
- 2011-12-08 MA MA36091A patent/MA34815B1/fr unknown
- 2011-12-09 UY UY0001033790A patent/UY33790A/es not_active Application Discontinuation
-
2013
- 2013-05-21 ZA ZA2013/03687A patent/ZA201303687B/en unknown
- 2013-05-27 CR CR20130246A patent/CR20130246A/es unknown
- 2013-06-07 CL CL2013001643A patent/CL2013001643A1/es unknown
- 2013-06-07 US US13/912,647 patent/US20140024653A1/en not_active Abandoned
- 2013-06-07 DO DO2013000131A patent/DOP2013000131A/es unknown
Also Published As
Publication number | Publication date |
---|---|
SG190368A1 (en) | 2013-06-28 |
WO2012078832A1 (en) | 2012-06-14 |
CR20130246A (es) | 2013-09-03 |
PE20140702A1 (es) | 2014-06-26 |
AU2011338354A1 (en) | 2013-06-27 |
BR112013014198A2 (pt) | 2016-09-13 |
JP2013544892A (ja) | 2013-12-19 |
KR20140011311A (ko) | 2014-01-28 |
AR084216A1 (es) | 2013-05-02 |
UY33790A (es) | 2012-07-31 |
RU2013131241A (ru) | 2015-01-20 |
DOP2013000131A (es) | 2013-11-15 |
NZ611581A (en) | 2015-02-27 |
US20140024653A1 (en) | 2014-01-23 |
CN103402518A (zh) | 2013-11-20 |
EP2648729A1 (en) | 2013-10-16 |
CL2013001643A1 (es) | 2014-03-28 |
CA2820748A1 (en) | 2012-06-14 |
MA34815B1 (fr) | 2014-01-02 |
TW201306837A (zh) | 2013-02-16 |
ZA201303687B (en) | 2014-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2013000508A1 (en) | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
MX2013006319A (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek. | |
MY183661A (en) | Treatment of cancer with tor kinase inhibitors | |
GEP20166455B (en) | Methods of administering pirfenidone therapy | |
PH12014501639A1 (en) | Pharmaceutical compositions and methods | |
MX344355B (es) | Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal. | |
MX2013003076A (es) | Terapeuticos contra cancer de mama. | |
GB201111485D0 (en) | Drug composition and its use in therapy | |
MX2016005294A (es) | Metodos para tratar y prevenir enfermedad injerto contra huésped. | |
MX2012007933A (es) | Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso. | |
MX2011011596A (es) | Perifosina y capecitabina como un tratamiento combinado para cancer. | |
MX2015014599A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. | |
MX2019008817A (es) | Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma. | |
PH12015500867B1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
MX2014000150A (es) | Sistemas, metodos y formulaciones para tratamiento de cancer. | |
WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
IN2014DN00123A (es) | ||
TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
BR112015005392A2 (pt) | formulação de comprimido de um inibidor de fosfatidilinositol 3-cinase | |
TN2013000247A1 (en) | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer | |
CO6721062A2 (es) | Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek | |
ECSP13012736A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
NI201300052A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
GT201300148A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de p13k y un inhibidor de mek |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |